Genprex (NASDAQ: GNPX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.120 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Genprex (NASDAQ: GNPX) through any online brokerage.
Other companies in Genprex’s space includes: Galectin Therapeutics (NASDAQ:GALT), Curis (NASDAQ:CRIS), Lumos Pharma (NASDAQ:LUMO), Bolt Biotherapeutics (NASDAQ:BOLT) and Viracta Therapeutics (NASDAQ:VIRX).
The latest price target for Genprex (NASDAQ: GNPX) was reported by Maxim Group on Friday, September 14, 2018. The analyst firm set a price target for 5.00 expecting GNPX to rise to within 12 months (a possible 233.33% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Genprex (NASDAQ: GNPX) is $1.5 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Genprex.
Genprex’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Genprex.
Genprex is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.